Insight Molecular Diagnostics Inc. Proceeds from Loans
Insight Molecular Diagnostics Inc. (IMDX) reported Proceeds from Loans of $1.14 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLoans · last filed 2020-11-12
- Insight Molecular Diagnostics Inc. proceeds from loans for the quarter ending 2020-09-30 was $0.00.
| Period end | Proceeds from Loans 3 month | Proceeds from Loans 6 month | Proceeds from Loans 9 month |
|---|---|---|---|
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.14M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $1.14M 10-Q · filed 2020-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |